国产多西他赛联合顺铂治疗晚期非小细胞肺癌疗效观察

目的观察国产多西他赛联合顺铂（DDP）治疗晚期非小细胞肺癌的近期疗效、临床受益和毒副反应。方法70例晚期NSCLC患者给予DP方案化疗：国产多西他赛75mg/m^2，静滴，d1；顺铂75mg/m^2，静滴，d1；21d为1周期。每例患者治疗2周期以上。结果全组完全缓解2例，部分缓解29例，稳定36例，进展3例，总有效率44．3％。中位生存期10．1个月，1年生存率38．6％（27／70）。临床受益疗效：行为状态阳性率51．4％，体重阳性率47．1％。毒副反应主要为骨髓抑制，脱发和消化系统反应。其中白细胞减少占75．7％，G-CSF治疗后较快恢复。结论国产多西他赛联合顺铂无论一线还是二线治疗晚期NSCLC近期疗效和临床受益良好，毒副反应可耐受。

Combined domestic docetaxel and cisplatin in treatment of advanced non-small-cell lung cancer(NSCLC)

Objective To investigate the therapeutic efficacy and toxicity of combination chemotherapy with domestic docetaxel and cisplatin in advanced non-small-cell lung cancer(NSCLC).Methods All patients received domestic docetaxel 75 mg/m2 and cisplatin 75 mg/m2 on day 1.Repeated dosage was given every 3 weeks.Efficacy and toxicity were recorded in every 2 cycles.Results ALL patients were assessed for efficacy.Among 70 patients,CR was 2.9%(2/70),PR was 41.4%(29/70),SD was 51.4%(36/70),PD was 4.3%(3/70).The overall response rate was 44.3%,the median survival rate was 10.1 months and 1 year survival rate was 38.6%.Clinical benefit response:masculine rate of action estate and avoirdupois were 51.4% and 47.1%.The main toxicities included myelosuppression,alopecia and vomiting.Hypolekocytosis was 75.7%.Conclusion The combination chemotherapy with domestic docetaxel and cisplatin in treating advanced NSCLC is effective and well-tolerated.